Biotechnology stocks have underperformed the broader equities market, private biotech companies have struggled to raise new capital without reducing their valuations, and biotech IPOs have been rare in number and inconsistent in return.
But there is optimism for the fourth quarter and into 2024. In a STAT News article, emerging companies & venture capital partner and practice co-head Brad Flint said that he has several biotech clients actively preparing for initial public offerings. He notes the biotech companies are taking steps to be ready to go public immediately when a favorable market window reopens.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.